ASCO Annual Meeting
ASCO Annual Meeting
June 16, 2017
1 min read
Save

10 highlights from the ASCO Annual Meeting

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.”

HemOnc Today presents 10 key updates from the meeting that reflect this theme and highlight key oncology research advances.

  • Treatment modifications that extended survival for childhood cancer survivors during the past several decades also reduced incidence of serious chronic disease in these individuals later in life. Read more.
  • Larotrectinib (LOXO-101, Loxo Oncology) — the first selective small-molecule pan-tropomyosin receptor kinase inhibitor — demonstrated clinical activity in adults and children with various tumors that had neurotrophic tyrosine receptor kinase gene fusions. Read more.
  • Women in the United States who underwent neoadjuvant therapy for triple-negative breast cancer appeared more likely than those in Europe and Asia to choose mastectomy instead of breast-conserving surgery. Read more.
  • Young patients with extramedullary relapse of acute lymphoblastic leukemia achieved potent and durable responses to single-agent chimeric antigen receptor T-cell immunotherapy. Read more.
  • The combination of nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) induced durable responses in previously treated patients with small cell lung cancer, according to results from the CheckMate 032 trial. Read more.
  • Aldoxorubicin (CytRX Corporation) monotherapy appeared well tolerated and may improve outcomes compared with standard treatments for relapsed/refractory soft tissue sarcoma. Read more.
  • Olaparib (Lynparza, AstraZeneca) significantly prolonged PFS compared with chemotherapy among patients with HER-2–negative metastatic breast cancer and germline BRCA mutations. Read more.
  • Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, and John Sweetenham, MD, FRCP, FACP, Chief Medical Editors of HemOnc Today, discuss key studies and themes from the ASCO Annual Meeting. Watch here.
  • Patients with metastatic cancer who used a web-based tool to regularly report symptoms while receiving chemotherapy reported a higher quality of life, had fewer emergency room visits and lived a median of 5 months longer than those who did not use the tool. Read more.
  • Patients with stage III colon cancer who stopped chemotherapy after 3 months had similar DFS at 3 years as those who continued chemotherapy for 6 months, according to a prospective analysis of six clinical trials presented during the plenary session. Read more.